Drugs

Cergomex Imports, LLC

FDA issued a warning letter to Cergomex Imports, LLC (Laredo, TX, United States) on Aug 4, 2023. Subject: Refusal to Provide Access to and Copying of Records.

From the letter: “Your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts,*1* we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.”

Laredo, TX, United StatesIssued Aug 4, 2023Posted Aug 8, 2023No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
1 finding · 1 issue type
Cited
No CFR or ISO section
Response due
Not stated in the letter
FDA asks for
2 actions
Named as possible actions
Refusal of admission
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Records & data integrityThe firm failed to respond to FDA's electronic and telephonic requests for records under section 704(a)(4), constituting a prohibited act under section 301(e).
Your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts,*1* we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.

What FDA requested

  • Respond to this letter within 48 hours to confirm or update your registration and/or drug listing status and indicate whether you will respond to the request for records and other information.
  • If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.

FDA Warning Letter

15 paragraphs · 1 section

Text as published on FDA.gov, retrieved Oct 20, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedAugust 4, 2023
AddressedDear Mr. Cerrillo Gonzalez

1Letter text

9 paragraphs

Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products including Sanetto Hands Sanitizer Gel. On August 16, 2022, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. A second email request was sent on August 31, 2022. These requests went unanswered. FDA contacted you by phone on October 24, 2022, and requested that you provide a response by October 31, 2022. We made multiple attempts to contact you by phone on August 1, 2023. Those attempts were unsuccessful and we were unable to leave a voice message. You failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.

It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).

Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts,1 we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.

Respond to this letter within 48 hours to confirm or update your registration and/or drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.

The Agency may conduct an inspection to verify information provided and/or to evaluate the compliance of your manufacturing operations.

Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-hand-sanitizers-consumers-should-not-use.

You may provide additional information for our consideration as we continue to assess your activities and practices.

Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.

Identify your response with FEI 3017539604 and ATTN: Joel Hustedt.

Sincerely, /S/ Francis Godwin Director Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research, FDA

__________________________

1 Since declaration of the COVID-19 public health emergency, a number of hand sanitizer products have been recalled due to quality issues including from substitution with other drug substances, impurities at unacceptable levels, and subpotency. The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing, to assess the overall quality of the drugs registered as manufactured by these firms.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Laredo, TX, United States
Letter posted date
Aug 8, 2023
Letter issue date
Aug 4, 2023
Addressed to
Owner
Inspection dates
Not recorded
Response window
Not verified in this snapshot. Consult the original letter.
Record length
479 words · 0 recorded redactions
Published status
No published close-out
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.